Concomitant inhibition of B7-H3 and PD-L1 expression by a novel and synthetic microRNA delivers potent antitumor activities in colorectal tumor models

Fang, Meng; Chen, Yinshuang; Yang, Man; Zhang, Hongjian; Wang, Weipeng

doi:10.1007/s10637-021-01123-4

Cited by 5 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yicun Han et al (65) found that PAMR could inhibit the proliferation of PD-L1 high-expressing esophageal cancer cells in vitro and reduce the expression of PD-L1. MicroRNA-34a (miR-34a), on the other hand, could effectively inhibit PD-L1 expression (66). By performing silencing and overexpression assays on miR-34, this study discovered that PAMR inhibited PD-L1 by increasing miR-34a levels.…”

Section: Chinese Medicine Monomers Sensitize Cancer Immunotherapymentioning

confidence: 97%

Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review

et al. 2023

View full text Add to dashboard Cite

The Programmed death-1 (PD-1) and its programmed death-ligand 1 (PD-L1) comprise the PD-1/PD-L1 axis and maintain tumor immune evasion. Cancer immunotherapy based on anti-PD-1/PD-L1 antibodies is the most promising anti-tumor treatment available but is currently facing the thorny problem of unsatisfactory outcomes. Traditional Chinese Medicine (TCM), with its rich heritage of Chinese medicine monomers, herbal formulas, and physical therapies like acupuncture, moxibustion, and catgut implantation, is a multi-component and multi-target system of medicine known for enhancing immunity and preventing the spread of disease. TCM is often used as an adjuvant therapy for cancer in clinical practices, and recent studies have demonstrated the synergistic effects of combining TCM with cancer immunotherapy. In this review, we examined the PD-1/PD-L1 axis and its role in tumor immune escape while exploring how TCM therapies can modulate the PD-1/PD-L1 axis to improve the efficacy of cancer immunotherapy. Our findings suggest that TCM therapy can enhance cancer immunotherapy by reducing the expression of PD-1 and PD-L1, regulating T-cell function, improving the tumor immune microenvironment, and regulating intestinal flora. We hope this review may serve as a valuable resource for future studies on the sensitization of immune checkpoint inhibitors (ICIs) therapy.

show abstract

Section: Chinese Medicine Monomers Sensitize Cancer Immunotherapymentioning

confidence: 97%

Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Nevertheless, miR-34a continues to be considered as a therapeutic target in cancer. For example, Meng et al [104] showed that synthesized miR-34a simultaneously decreased the expression of PD-L1 as well as the checkpoint molecule, B7-H3, which inhibits tumor antigen-specific immune responses, and it demonstrated superior antitumor activity in colorectal cancer models in vitro and in vivo.…”

Section: Mir-34mentioning

confidence: 99%

Clinical Implementation of MicroRNAs in Cancer Immunology

Schwarzenbach

2024

IJTM

View full text Add to dashboard Cite

MicroRNAs (miRNAs), or small non-coding RNAs, modulate the expression of mRNAs and, consequently, a variety of signal transduction pathways. Due to their dysregulation in cancer, they exert oncogenic pressure and have an impact on the immune system with their protective functions. These immunosuppressive characteristics of miRNAs in cancer promote cancer progression and metastasis, causing the dysregulation of immune cells and the immune escape of tumor cells. In contrast, there are also tumor suppressor miRNAs that are able to activate the immune system. Therefore, studies on the altered expression of miRNAs that consider both the oncogenic and tumor-suppressive aspects of miRNAs have become an important research field for advancing immunotherapeutic interventions using miRNAs or their inhibitors as therapeutics. In the current review, their potential in the immunomodulation of immune cells and their use as immune stimulatory molecules to elicit specific cytotoxic responses against the tumor are discussed.

show abstract

“…The combination of miR-34a-mimic and antisense-miR-10b is also being studied in BC models [ 180 ]. Meng et al showed that the synthesized miR-34a analog NS-MX3 simultaneously decreased the expression of B7-H3 and PD-L1 and demonstrated superior antitumor activity in CRC models in vitro and in vivo [ 199 ].…”

Section: Prospects For Mirna-based Therapymentioning

confidence: 99%

The Features of Immune Checkpoint Gene Regulation by microRNA in Cancer

Kipkeeva

Музаффарова

Korotaeva

et al. 2022

IJMS

View full text Add to dashboard Cite

Currently, the search for new promising tools of immunotherapy continues. In this regard, microRNAs (miRNAs) that influence immune checkpoint (IC) gene expression in tumor and T-cells and may be important regulators of immune cells are considered. MiRNAs regulate gene expression by blocking mRNA translation. An important feature of miRNA is its ability to affect the expression of several genes simultaneously, which corresponds to the trend toward the use of combination therapy. The article provides a list of miRNAs acting simultaneously on several ICs and miRNAs that, in addition to IC, can regulate the expression of targeted therapy genes. There is dependence of miRNA interactions with IC genes on the type of cancer. The analysis of the accumulated data demonstrates that only about 14% (95% CI: 9.8–20.1%) of the studied miRNAs regulate the expression of specific IC in more than one type of cancer. That is, there is tumor specificity in the miRNA action on ICs. A number of miRNAs demonstrated high efficiency in vitro and in vivo. This indicates the potential of miRNAs as promising agents for cancer immunotherapy. Additional studies of the miRNA–gene interaction features and the search for an optimal miRNA mimic structure are necessary.

show abstract

Concomitant inhibition of B7-H3 and PD-L1 expression by a novel and synthetic microRNA delivers potent antitumor activities in colorectal tumor models

Cited by 5 publications

References 37 publications

Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review

Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review

Clinical Implementation of MicroRNAs in Cancer Immunology

The Features of Immune Checkpoint Gene Regulation by microRNA in Cancer

Contact Info

Product

Resources

About